Abstract
Bilayered tablets of Divalproex sodium for once-a-day administration were prepared using a hydrophilic and hydrophobic polymer as release retarding agents. This technology was found to be more effective than a simple matrix tablet with a mixture of the above polymers in order to retard the drug release for a period of 24 h. The drug release profile was strongly dependent on the presence of wicking agent, pathlength of hydrophobic layer, and hardness of tablet. f1 value of 6.92 and f2 value of 76.72 indicated similarity between the release profiles of batch BT3 and reference tablet (Depakote ® ER) with the target release of over 55% within 12 h and over 85% within 18 h. Mathematical modeling using Korsmeyer-Peppas equation indicated that the release followed a combination of diffusion and erosion mechanism.
Keywords: Bilayered tablets, Divalproex sodium, HPMC, Ethylcellulose, Extended release
Current Drug Delivery
Title: Development of Extended Release Divalproex Sodium Tablets Containing Hypdrophobic and Hydrophilic Matrix
Volume: 6 Issue: 3
Author(s): S. Chakraborty, J. K. Pandit and A. Srinatha
Affiliation:
Keywords: Bilayered tablets, Divalproex sodium, HPMC, Ethylcellulose, Extended release
Abstract: Bilayered tablets of Divalproex sodium for once-a-day administration were prepared using a hydrophilic and hydrophobic polymer as release retarding agents. This technology was found to be more effective than a simple matrix tablet with a mixture of the above polymers in order to retard the drug release for a period of 24 h. The drug release profile was strongly dependent on the presence of wicking agent, pathlength of hydrophobic layer, and hardness of tablet. f1 value of 6.92 and f2 value of 76.72 indicated similarity between the release profiles of batch BT3 and reference tablet (Depakote ® ER) with the target release of over 55% within 12 h and over 85% within 18 h. Mathematical modeling using Korsmeyer-Peppas equation indicated that the release followed a combination of diffusion and erosion mechanism.
Export Options
About this article
Cite this article as:
Chakraborty S., Pandit K. J. and Srinatha A., Development of Extended Release Divalproex Sodium Tablets Containing Hypdrophobic and Hydrophilic Matrix, Current Drug Delivery 2009; 6 (3) . https://dx.doi.org/10.2174/156720109788680822
DOI https://dx.doi.org/10.2174/156720109788680822 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology On the Psychotropic Effects of Carbon Dioxide
Current Pharmaceutical Design Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Sleep Disordered Breathing: Alternatives to CPAP Therapy
Current Respiratory Medicine Reviews Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry Efficacy and Tolerability of Naltrexone in the Management of Alcohol Dependence
Current Pharmaceutical Design Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Novel Treatment Options of Binge Eating Disorder
Current Medicinal Chemistry Benefits and Limitations of Polymorphic and Amorphous Forms of Active Pharmaceutical Ingredients
Current Pharmaceutical Design Sigma-2 Receptor as a Potential Drug Target
Current Medicinal Chemistry Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia
Current Pharmaceutical Biotechnology Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Novel Purine Nucleoside Analogues for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Impact of Opioid Receptor, Mu 1 (OPRM1) Polymorphisms on Pain Sensitivity and Clinical Response to Opioid Analgesic Therapy
Current Pharmacogenomics and Personalized Medicine Biologic and Novel Therapy of the Inflammatory Bowel Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Current Pharmaceutical Biotechnology Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety